EGI
KZR

EAM Global Investors’s Kezar Life Sciences KZR Stock Holding History

EAM Global Investors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,643
Closed -$2.43M – 224
2022
Q1 		$2.43M Sell
14,643
-4,034
-22% -$579K 0.45% 75
2021
Q4 		$3.12M Buy
+18,677
New +$2.11M 0.55% 55

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM Global Investors's KZR Position: Q2 2022 in Review

EAM Global Investors sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 14,643 shares — an estimated $2.43M sold.

EAM Global Investors first reported a position in KZR in Q4 2021 and held it in 2 quarters. The position peaked at $3.12M in Q4 2021. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

  • EAM Global Investors reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
  • EAM Global Investors sold 14,643 Kezar Life Sciences shares in Q2 2022, an estimated $2.43M.
  • EAM Global Investors first reported a position in Kezar Life Sciences in Q4 2021 and held it in 2 quarters.
  • EAM Global Investors's Kezar Life Sciences position peaked at $3.12M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on EAM Global Investors's 13F filing for Q2 2022, filed 12 Aug 2022.